Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www-thieme-connect-de.accesdistant.sorbonne-universite.fr/rss/thieme/en/10.1055-s-00000004.xml
Download PDF
Aktuelle Neurologie 2010; 37(10): 518-523
DOI: 10.1055/s-0030-1265985
DOI: 10.1055/s-0030-1265985
Übersicht
© Georg Thieme Verlag KG Stuttgart · New YorkImmuntherapie bei Myasthenia gravis und Lambert-Eaton-Syndrom
Teil 2: Intravenöse Immunglobuline und PlasmaaustauschverfahrenImmunotherapy for Myasthenia Gravis and Lambert-Eaton Myasthenic SyndromePart 2: Intravenous Immunoglobulins and Apheresis TechniquesFurther Information
Publication History
Publication Date:
05 January 2011 (online)
Zusammenfassung
Die intravenöse Gabe hoch dosierter Immunglobuline stellt ebenso wie der Plasmaaustausch und die (semi)selektive Immunadsorption eine wichtige Behandlungsoption bei myasthenen Krisen bzw. Exazerbationen sowie auch bei der Behandlung schwerster chronischer Myasthenien dar. Die genannten Verfahren sind damit wichtiger Bestandteil des Therapiekonzepts myasthener Syndrome und ergänzen die in der vorhergehenden Publikation dargestellten medikamentösen Behandlungsmöglichkeiten. In der vorliegenden Publikation geht der Ärztliche Beirat der Myasthenie-Gesellschaft (DMG) auf die Indikationen, Studienergebnisse und Komplikationsmöglichkeiten der genannten Verfahren sowie ihren Stellenwert ein.
Abstract
Intravenous immunoglobulins (IVIG), plasma exchange and semi-selective immunoadsorption represent important options for the treatment of myasthenic crisis or its exacerbations as well as severe chronic myasthenia gravis. They are therefore indispensable components of a comprehensive treatment concept for myasthenic syndromes and complete individual drug treatment which has been discussed in the preceding part of this review. In this publication, the Advisory Board of the German Myasthenia Society (DMG) discusses the indications, study results, adverse events and complications of IVIG, plasma exchange and immunoadsorption and their importance within the treatment concept.
Schlüsselwörter
Myasthenia gravis - Lambert-Eaton myasthenes Syndrom - Immuntherapie - Immunglobuline - Aphereseverfahren
Keywords
myasthenia gravis - Lambert-Eaton myasthenic syndrome - immunotherapy - immunoglobulins - apheresis techniques
Literatur
- 1 NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA. 1990; 264 3189-3193
- 2 Dalakas M C. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002; 59 S13-21
- 3 Tackenberg B, Jelcic I, Baerenwaldt A et al. Impaired inhibitory FCγ receptor IIB expression on B cells in CIDP. Proc Ntl Acad Sci USA. 2009; 106 4788-4792
- 4
Stangel M, Gold R.
Einsatz intravenöser Immunglobuline in der Neurologie.
Ein evidenzbasierter Konsens: Update 2010.
Nervenarzt.
2010;
Doi
DOI: 10.1007/s00115-010-3059-8
MissingFormLabel
- 5 Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007; 68 837-841
- 6 Gajdos P, Tranchant C, Clair B Myasthenia Gravis Clinical Study Group et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol. 2005; 62 1689-1693
- 7 Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2008; CD002277
- 8 Rønager J, Ravnborg M, Hermansen I et al. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001; 25 967-973
- 9 Gajdos P, Chevret S, Clair B Myasthenia Gravis Clinical Study Group et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol. 1997; 41 789-796
- 10 Wolfe G I, Barohn R J, Foster B M Myasthenia Gravis-IVIG Study Group et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve. 2002; 26 549-552
- 11 Qureshi A I, Choudhry M A, Akbar M S et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999; 52 629-632
- 12 Seneviratne J, Mandrekar J, Wijdicks E F et al. Predictors of extubation failure in myasthenic crisis. Arch Neurol. 2008; 65 929-933
- 13 Thomas C E, Mayer S A, Gungor Y et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997; 48 1253-1260
- 14 Tatay J, Díez-Tejedor E, Frank A et al. Association of plasmapheresis and high doses of intravenous immunoglobulins in the treatment of myasthenia gravis. Rev Neurol. 1997; 25 1402-1406
- 15 Stricker R B, Kwiatkowska B J, Habis J A et al. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol. 1993; 50 837-840
- 16 Wegner B, Ahmed I. Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis. Clin Neurol Neurosurg. 2002; 105 3-8
- 17 Achiron A, Barak Y, Miron S et al. Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve. 2000; 23 551-555
- 18 Hilkevich O, Drory V E, Chapman J et al. The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis. Clin Neuropharmacol. 2001; 24 173-176
- 19 Shibata-Hamaguchi A, Samuraki M, Furui E et al. Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis. Acta Neurol Scand. 2007; 116 406-408
- 20 Saulat B, Maertens P, Hamilton W J et al. Anti-musk antibody after thymectomy in a previously seropositive myasthenic child. Neurology. 2007; 69 803-804
- 21 Takahashi H, Kawaguchi N, Nemoto Y et al. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis. J Neurol Sci. 2006; 247 239-241
- 22 Evoli A, Tonali P A, Padua L et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003; 126 2304-2311
- 23 Lebrun C, Bourg V, Tieulie N et al. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol. 2009; 16 246-250
- 24 Hain B, Jordan K, Deschauer M et al. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve. 2006; 33 575-580
- 25 Bain P G, Motomura M, Newsom-Davis J et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996; 47 678-683
- 26 Tim R W, Massey J M, Sanders D B. Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. Ann N Y Acad Sci. 1998; 841 823-826
- 27 Rich M M, Teener J W, Bird S J. Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin. Muscle Nerve. 1997; 20 614-615
- 28 Tackenberg B, Hemmer B, Oertel W H et al. Immunosuppressive treatment of ocular myasthenia gravis. BioDrugs. 2001; 15 369-378
- 29 Toyka K V, Drachman D B, Griffin D E et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 1977; 296 125-131
- 30 Pinching A J, Peters D K, Newsom-Davis J. Plasma exchange in myasthenia gravis. Lancet. 1977; 309 428-429
- 31 Bucka C, Köhler W, Hertel G et al. Immunadsorption bei Myasthenia gravis. Wirkungsweise, immunologische Parameter und klinischer Verlauf. Akt Neurol. 1993; 20 207-213
- 32 Goto H, Matsuo H, Nakane S et al. Plasmapheresis affects T helper type-1 / T helper type-2 balance of circulating peripheral lymphocytes. Ther Apher. 2001; 5 494-496
- 33 Ptak J, Lochmann J. Immunoadsorption and complement activation. Transfus Apher Sci. 2005; 32 263-267
- 34 Yeh J H, Wang S H, Chien P J et al. Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis. Eur J Neurol. 2009; 16 1318-1322
- 35 Lehmann H C, Hartung H P, Hetzel G R et al. Plasma exchange in neuroimmunological disorders: Part 2. Treatment of neuromuscular disorders. Arch Neurol. 2006; 63 1066-1071
- 36 Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics. 2008a; 5 535-541
- 37 Wagner S, Grützmacher W. Langzeitbehandlung der therapierefraktären Myasthenia gravis mittels therapeutischer Apherese. Nephro-News. 2007; No. 9 31
- 38 Triantafyllou N I, Grapsa E I, Karaziou E et al. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up. Ther Apher Dial. 2009; 13 174-178
- 39 Winters J L, Pineda A A. New directions in plasma exchange. Curr Opin Hematol. 2003; 10 424-428
- 40 Assessment of plasmapheresis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1996; 47 840-843
- 41 National Institutes of Health Consensus Development Conference . The use of therapeutic plasmapheresis for neurological disorders. Transfus Med Rev. 1988; 2 48-53
- 42 Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002; CD002275
- 43 Newsom-Davis J, Wilson S G, Vincent A et al. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet. 1979; 1 464-468
- 44 Sutton D M, Nair R C, Rock G. Complications of plasma exchange. Transfusion. 1989; 29 124-127
- 45 Köhler W, Kalischewski P, Bucka C et al. Immunoadsorption versus plasma exchange: A randomized clinical trial in Myasthenia Gravis. Kidney Blood Pressure Res. 2000; 23 214-347
- 46 Zisimopoulou P, Lagoumintzis G, Poulas K et al. Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients’ sera using Escherichia coli-expressed receptor domains. J Neuroimmunol. 2008; 200 133-141
- 47 Skeie G O, Apostolski S, Evoli A et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010; 17 893-902
- 48 Haupt W F, Rosenow F, van der Ven C et al. Immunoadsorption in Guillain-Barré syndrome and Myasthenia Gravis. Therapeutic Apheresis. 2000; 4 195-197
- 49 Haupt F W, Klingel R. Indications for therapeutic apheresis in neurologic diseases. Kidney Blood Pressure Research. 2001; 24 418-421
- 50 Marx C, Marx M, Endler S et al. Safe and effective long-term outpatient immunoadsorption (IA) in a patient with severe Myasthenia Gravis (Ossermann IV). Kidney Blood Pressure Res. 2000; 23 214-347 (abstract)
- 51 Wagner S, Janzen R WC, Mohs C et al. Langzeitbehandlung der therapierefraktären Myasthenia gravis mittels Immunadsorption. Dtsch Med Wschr. 2008; 133 2377-2382
- 52 Zeitler H, Ulrich-Merzenich G, Hoffmann L et al. Long-term effects of a multimodal approach including immunoadsorption for the treatment of myasthenic crisis. Artif Organs. 2006; 30 597-605
- 53 Antozzi C, Berta E, Confalonieri P et al. Protein-A immunoadsorption in immunosuppression-resistant myasthenia gravis. Lancet. 1994; 343 124
- 54 Benny W B, Sutton D M, Oger J et al. Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients. Transfusion. 1999; 39 682-687
- 55 Grob D, Simpson D, Mitsumoto H et al. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology. 1995; 45 338-344
- 56 Gold R, Krenzer M, Klinker E et al. Efficacy and Safety of Immunoadsorption vs Plasmapheresis vs
Combination for Treatment of Myasthenic Crisis: Comparative Retrospective Study
on 72 Patients. Abstract S57.002 und Vortrag at 60th Annual Meeting
American Academy of Neurology Chicago; 2008b
MissingFormLabel
- 57 Hosokawa S, Oyamaguchi A. Safety, stability, and effectiveness of immunoadsorption under membrane plasmapheresis treatment for myasthenia gravis. ASAIO Trans. 1990; 36 M207-208
- 58 Ishizeki J, Nishikawa K, Kunimoto F et al. Postoperative myasthenic crisis successfully treated with immunoadsorption therapy. J Anaesth. 2005; 19 320-322
- 59 Sato T, Ishigaki Y, Komiya T et al. Therapeutic immunoadsorption of acetylcholine receptor antibodies in myasthenia gravis. Ann N Y Acad Sci. 1988; 540 554-556
- 60 Shibuya N, Sato T, Osame M et al. Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry. 1994; 57 578-581
- 61 Szpirt W, Somnier F, Nielsen F C et al. Elimination of IgG subclasses of anti-acetylcholine receptor antibodies in myasthenic plasma by immunoadsorption to protein A. Life Support Syst. 1985; 3 (S 01) 351-355
- 62 Ichikawa M, Koh C S, Hata Y et al. Immunoadsorption plasmapheresis for severe generalized myasthenia gravis. Arch Child Dis. 1993; 69 236-238
- 63 Besinger U A, Toyka K V, Hömberg M et al. Myasthenia gravis: Long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology. 1983; 33 1316-1321
- 64 Yeh J H, Chiu H C. Immunoadsorption therapy for myasthenia gravis: study on the adsorption capacity of an immunoadsorption column. J Microbiol Immunol Infect. 1999a; 32 121-125
- 65 Yeh J H, Chiu H C. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol. 2000; 247 510-513
- 66 Haas M, Mayr N, Zeitlhofer J et al. Long-term treatment of Myasthenia gravis with immunoadsorption. J Clin Apheresis. 2002; 17 84-87
- 67 Ishikawa S, Takei Y, Tokunaga S et al. Response to immunoadsorption and steroid therapy in a patient with carcinomatous Lambert-Eaton myasthenia syndrome accompagnied by disturbed consciousness. Rinsho Skinkeigaku. 2000; 40 459-463
- 68 Berta E, Confalonieri P, Simoncini O et al. Removal of antiacetylcholine receptor antibodies by protein-A immunoadsorption in myasthenia gravis. Int J Artif Organs. 1994; 17 603-608
- 69 Yeh J H, Chiu H C. Optimal volume of processed plasma and total number of selective plasmapheresis sessions in the treatment of patients with severe generalized myasthenia gravis. J Clin Apher. 1999b; 14 177-180
Prof. Dr. med. Thomas Henze
Reha-Zentrum Nittenau
Eichendorffstr. 21
93149 Nittenau
Email: t.henze@rz-ni.de